# INTERNATIONAL JOURNAL OF AYURVEDA360



# PEER-REVIEWED BIMONTHLY JOURNAL



www.ayurveda360.in/journal

ISSN PRINT: 3048-7382 ONLINE: 3048-7390


2025 VOLUME 1 ISSUE 6 MAY-JUNE



VATARAKTA

# INTERNATIONAL JOURNAL OF AYURVEDA360

E-ISSN : 3048-7390 PRINT ISSN : 3048-7382 VOLUME 1 ISSUE 6 MAY-JUNE 2025



www.ayurveda360.in

# DOI: 10.63247/3048-7390.vol.1.issue6.6

# Ayurvedic Management of Systemic Lupus Erythematosus with Respect to *Vatapradhana Vatarakta*: A Case Report Singh R<sup>1</sup>, Khagram R<sup>2</sup>

- 1. Dr. Rashmi Singh, PG Scholar, Dept. of Pancakarma, ITRA, Jamnagar, <u>https://orcid.org/0009-0007-5427-3898</u>
- 2. Dr. Rita Khagram, Associate Professor, Dept. of Pancakarma, ITRA, Jamnagar, https://orcid.org/0009-0002-9065-9628

#### ABSTRACT

**Introduction**: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disorder affecting connective tissues, where the immune system attacks healthy body tissues like skin, joints, kidneys, and other organs. Symptoms include fever, fatigue, myalgia, arthralgia, arthritis, malar rash, and oral ulcers. SLE can be correlated with *Vatarakta* in Ayurveda, presenting symptoms such as pain, swelling, and stiffness at multiple joints with blackish discoloration.

**Objective**: To explore the Ayurvedic management of Systemic Lupus Erythematosus (SLE) with reference to *Vatapradhan Vatarakta*.

**Materials and Methods**: As vitiated *Vata* is involved in the pathology of *Vatarakta*, *Basti* (an Ayurvedic enema therapy) is considered the most effective treatment for relieving this condition. *Mridu Virechana* (mild purgation) was selected before *Basti* to detoxify the body, considering the patient's history of steroid use.

**Results and Discussion**: Both *Vata* and *Rakta* were vitiated, which contributed to the symptoms. The management plan focused on addressing both *Vata* and *Rakta Dushti* (imbalance). The detoxifying effects of *Virechana* were aimed at reducing the harmful impact of steroids, followed by *Basti* to balance *Vata*.

**Conclusion**: This case report highlights the potential of Ayurveda in managing autoimmune disorders like SLE by targeting the vitiation of *Vata* and *Rakta* through specific treatments like

475

Basti and Virechana.

Keywords: Vatarakta, SLE, Basti, Virechana, Vatapradhan Vatarakta, Ayurveda

| CORRESPONDING AUTHOR                                                                                                     | HOW TO CITE THIS ARTICLE?                                                                                                                                                                                                                                                     | TO BROWSE |
|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Dr. Rashmi Singh, PG Scholar,<br>Dept. of Pancakarma, ITRA,<br>Jamnagar.<br>Email:<br><u>singhrashmi250841@gmail.com</u> | Singh, R., & Khagram, R. (2025).<br>Ayurvedic management of systemic<br>lupus erythematosus with respect to<br>Vatapradhana Vatarakta: A case report.<br><i>International Journal of Ayurveda360</i> ,<br>1(6), 475-483, <u>https://doi.org/3048-<br/>7390.vol.1.issue6.6</u> |           |

| Manuscript | Review               | Review     | Review           | Final Updated      |
|------------|----------------------|------------|------------------|--------------------|
| Received   | Round 1              | Round 2    | Round 3          | Received           |
| 11/04/2025 | 25/04/2025           | 28/04/2025 | 18/05/2025       | 11/06/2025         |
| Accepted   | Conflict of Interest | Funding    | Ethical Approval | Plagiarism Checker |
| 12/06/2025 | NIL                  | NIL        | Consent Received | 9%                 |

# Licensing and Distribution

|                    | This work is licensed under a Creative Commons Attribution 4.0 International                  |  |  |  |  |
|--------------------|-----------------------------------------------------------------------------------------------|--|--|--|--|
|                    | License. ( <u>https://creativecommons.org/licenses/by/4.0/</u> ) You are free to share, copy, |  |  |  |  |
| © creative commons | redistribute, remix, transform, and build upon this work for any purpose, even                |  |  |  |  |
| Commons            | commercially, provided that appropriate credit is given to the original author(s) and source, |  |  |  |  |
|                    | a link to the license is provided, and any changes made are indicated.                        |  |  |  |  |



International Journal of Ayurveda360 2025; 1(6)

This journal is published under the tradename Ayurveda360, registered under UDYAM-KR-27-0044910.

# Introduction

Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune, multisystem connective tissue disorder with a wide spectrum of clinical manifestations. It affects predominantly of women with reproductive age and presents symptoms such as fever, fatigue, myalgia, arthralgia, arthritis, malar rash, oral ulcers, and systemic involvement including neurological renal and complications. In India, its prevalence ranges from 14 to 60 per 100,000 population [1].

From the Ayurvedic perspective, the clinical features of SLE can be correlated with Vatapradhana Vatarakta, a disease resulting from the simultaneous vitiation of Vata and Rakta [2]. The aggravated Vata. obstructed by morbid Rakta. disturbs the balance of the body and gives rise to various symptoms. Vatarakta is known by several synonyms such as Khuda, Vatabalasa, and Adhyavata[3]. The term Adhyavata reflects the disease's tendency to affect individuals with a delicate constitution (Sukumara Purusha) and those indulging in unwholesome dietetic habits and sedentary lifestylesfactors often affluent seen in populations[4].

This case report presents the *Ayurvedic* approach to managing a confirmed case of SLE, highlighting the

diagnostic correlation with *Vatapradhana Vatarakta* and the effectiveness of Panchakarma and Ayurvedic medication.

# **Patient Information**

A 32-year-old female patient presented to the Panchakarma OPD at ITRA, Jamnagar, with complaints of:

- Pain, swelling, and stiffness in bilateral hands, feet, knees, and elbows for the past 3 years
- Blackish discoloration over affected joints
- Intermittent episodes of fever for the past 3 years
- Anxiety symptoms for the past 4 years

She had known history of а Hypertension (2 years) and had tested ANA positive in 2022. Her allopathic treatment included Hydroxychloroquine (HCQ) and Prednisolone for SLE, and Telmisartan 20 mg daily for hypertension. The patient was admitted to the female ward of the Panchakarma Department at ITRA, Jamnagar for Ayurvedic management. Informed consent was obtained before initiating examination and therapy.

# **Clinical Findings**

# Table No. 1 : General Examination

| Parameter               | Value          |
|-------------------------|----------------|
| Pulse Rate              | 67/min         |
| Heart Rate              | 70 beats/min   |
| <b>Respiratory Rate</b> | 16 breaths/min |

International Journal of Ayurveda360 | 2025; 1(6)

Singh R, Khagram R. Case Report: SLE Treated as Vatapradhana Vatarakta

| Blood Pressure   | 130/80 mmHg |  |
|------------------|-------------|--|
| Body Temperature | 99.6 °F     |  |

Table No. 2 : Pain Assessment (VASScore)

| Joint           | VAS Score (0–<br>10) |
|-----------------|----------------------|
| Bilateral Elbow | 9                    |
| Bilateral Hands | 9                    |
| Bilateral Feet  | 10                   |
| Bilateral Knees | 10                   |

# Table No. 3 : Stiffness Assessment

| Stiffness<br>Grade | Description                                             | Score<br>(BT) |  |
|--------------------|---------------------------------------------------------|---------------|--|
| 0                  | No stiffness                                            | 0             |  |
| 1                  | Mild (can perform daily activities)                     | 0             |  |
| 2                  | Moderate<br>(difficulty<br>performing daily<br>routine) | 0             |  |
| 3                  | Severe (unable to<br>perform daily<br>activities)       | 3             |  |

Table No. 4 : Swelling Assessment(Measured in Inches)

| Joint | Right<br>(inches) | Left<br>(inches) |
|-------|-------------------|------------------|
| Elbow | 8.5               | 8.5              |
| Hands | 8.3               | 8.3              |
| Feet  | 11.3              | 11.5             |
| Knees | 16.9              | 16.5             |

# Timeline of Clinical Events

# Table No. 5 : Clinical Chronology

| Sr. | Clinical Events /                                                                                    | <b>Duration</b> / |
|-----|------------------------------------------------------------------------------------------------------|-------------------|
| No. | Complaints                                                                                           | Onset             |
| 1   | Pain,swelling,stiffness in bilateralhands and feet with                                              | 3 years           |
| 2   | discoloration<br>Pain, swelling,<br>stiffness in bilateral<br>knees and elbows<br>with discoloration | 3 years           |
| 3   | Intermittent fever                                                                                   | 3 years           |
| 4   | Anxiety symptoms                                                                                     | 4 years           |
| 5   | Diagnosis of<br>Hypertension                                                                         | 2 years           |
| 6   | ANA Positive                                                                                         | 2022              |

# **Diagnostic Assessment**

Based on the patient's clinical presentation-including symmetrical joint pain with edema, blackish discoloration, intermittent fever, positive ANA report, and history of autoimmune involvementthe condition was diagnosed as Systemic Erythematosus (SLE). Lupus In Ayurveda, the clinical features were assessed in terms of Vatapradhana Vatarakta, characterized by aggravated Vata obstructed by vitiated Rakta, resulting in musculoskeletal and systemic disturbances.

International Journal of Ayurveda360 | 2025; 1(6)

| Image 1 : Investigation | on Report |
|-------------------------|-----------|
|-------------------------|-----------|

| Specimen :                                       | Coll.                                                      |                   |                                                                                                                                                           |
|--------------------------------------------------|------------------------------------------------------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| SERUM SPL                                        | 28/03/2022 19:0                                            | 2: Lab Collection |                                                                                                                                                           |
| <u>Test Parameter</u><br>ANA Subset<br>ANA - IFA | Testing                                                    | <u>Result(s)</u>  | Biological Reference Interval (Adult)                                                                                                                     |
| ANA by IFA                                       | (Dilution 1:100)                                           | Detected +3       | Not detected                                                                                                                                              |
| Pattern                                          |                                                            | Speckled gran     | nulated                                                                                                                                                   |
| ANA Subset                                       | t by Immunoblot                                            |                   |                                                                                                                                                           |
| n RNP / Sm                                       | (U1-nRNP)                                                  | +++               | Not detected                                                                                                                                              |
| Sm                                               |                                                            | Not detected      | Not detected                                                                                                                                              |
| SS - A                                           |                                                            | Not detected      | Not detected                                                                                                                                              |
| RO - 52                                          |                                                            | Not detected      | Not detected                                                                                                                                              |
| SS - B                                           |                                                            | (+)               | Not detected                                                                                                                                              |
| Scl - 70                                         |                                                            | Not detected      | Not detected                                                                                                                                              |
| PM - Scl                                         |                                                            | Not detected      | Not detected                                                                                                                                              |
| Jo - 1                                           |                                                            | Not detected      | Not detected                                                                                                                                              |
| CENP B                                           |                                                            | Not detected      | Not detected                                                                                                                                              |
| PCNA                                             |                                                            | Not detected      | Not detected                                                                                                                                              |
| ds DNA                                           |                                                            | Not detected      | Not detected                                                                                                                                              |
| Nucleosome                                       | 5                                                          | (+)               | Not detected                                                                                                                                              |
| Histones                                         |                                                            | Not detected      | Not detected                                                                                                                                              |
| Rib P - Prote                                    | in                                                         | Not detected      | Not detected                                                                                                                                              |
| AMA - M2                                         |                                                            | Not detected      | Not detected                                                                                                                                              |
| DFS70                                            |                                                            | Not Detected      | Not Detected                                                                                                                                              |
| Interpretation                                   | n                                                          |                   |                                                                                                                                                           |
| S/o MCTD<br>Needs clini                          | f U1-nRNP.<br>cal correlation.<br>cific ELISA if required. |                   |                                                                                                                                                           |
|                                                  |                                                            |                   | henever required. * Subject to Vadodara Jurisdiction.                                                                                                     |
| ntres * Raopu                                    | lourse Ph. : 2341442<br>ra Ph. : 2437861                   | * Nizampura       | Ph.:         2495193         * Waghodia Road         Ph.:         2522555           Ph.:         2780342         * Dabhoi         Ph.:         6351979438 |
| * Gorwa                                          |                                                            |                   | Ph. : 2780342 * Debnot Ph. : 6351979438<br>Ph. : 2638224 * Ratpipla Ph. : (02640) 224442                                                                  |

Toprani Advanced Lab Systems

Dr. Harsukh Toprani M.D. (Path & B

# **Therapeutic Intervention**

Considering the chronicity of symptoms and the patient's intolerance to strong *Shodhana* (purificatory) therapies, a *Mridu Shodhana* (mild purification) approach was adopted. A classical *Virechana Karma* followed by *Ksheera Basti*, as mentioned in the *Siddhi Sthana* of *Charaka Samhita*, was implemented.

| Sr.<br>No | Modality                                   | Drug               | Dose                               | Anupana                       | Time of<br>Administratio<br>n | Durati<br>on |
|-----------|--------------------------------------------|--------------------|------------------------------------|-------------------------------|-------------------------------|--------------|
| 1         | Deepana–<br>Pachana                        | Aampachaka<br>Vati | 2 tablets                          | Lukewarm<br>water             | Twice daily before meals      | 5 days       |
| 2         | <i>Snehapana</i><br>(Internal<br>oleation) | Go-Ghrita          | Started<br>with 30 ml<br>up to 220 | As needed<br>with<br>lukewarm | Morning (7:00–<br>7:30 AM)    | 5 days       |

## **Table 6: Virechana Karma Protocol**

International Journal of Ayurveda360 | 2025; 1(6)

10.63247/3048-7390.vol.1.issue6.6

479

|   |                                          |                        | ml                            | water             |                                                  |        |
|---|------------------------------------------|------------------------|-------------------------------|-------------------|--------------------------------------------------|--------|
| 3 | Sarvanga<br>Abhyanga<br>(massage)        | Bala Taila             | Q.S.                          |                   | -                                                | 4 days |
| 4 | Sarvanga<br>Bashpa<br>Swedana            | _                      | —                             | _                 | —                                                | 4 days |
| 5 | Virechana<br>Karma<br>(purgation)        | Aragvadhadi<br>Avaleha | 100 gm                        | Lukewarm<br>water | After Shleshma<br>Kala (~10:30<br>AM)            | 1 day  |
| 6 | Samsarjana<br>Krama (dietary<br>regimen) | _                      | As per<br>Madhyama<br>Shuddhi | _                 | Upon onset of<br>hunger post<br><i>Virechana</i> | 5 days |

# Ksheera Basti Protocol

*Ksheera Basti* is considered a *Mridu Niruha Basti*, suitable for patients where *Vamana* and other *Shodhana* therapies are contraindicated. It provides both nutritional and therapeutic benefits and is particularly beneficial in *Vata-Rakta* conditions.

| Sr.<br>No. | Modality                        | Drug/Formulation                                                                                                                                             | Dose/Quan<br>tity       | Duration |
|------------|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|----------|
| 1          | Sthanik Abhyanga                | Sahachara Taila                                                                                                                                              | Q.S.                    | 8 days   |
| 2          | Sthanik Nadi<br>Swedana         | Dashamoola Kwatha                                                                                                                                            | _                       | 8 days   |
| 3          | <i>Ksheera Basti</i><br>Mixture | Honey: 80 g<br>Saindhava: 12 g<br>Guduchi Ghrita: 80 g<br>Guduchi Kalka: 25 g<br>Punarnavashtaka Kwatha &<br>Dashamoola Kwatha Siddha<br>Ksheerapaka: 450 ml | As above<br>composition | 8 days   |

 Table 7 : Ksheera Basti Ingredients

# **Follow-Up and Outcomes**

The patient remained hospitalized for 28 days during which *Virechana* and *Ksheera Basti* therapies were completed. Notable clinical improvements were observed, particularly in joint pain, stiffness, and swelling, with increased functional mobility. All clinical examinations were repeated post-treatment, showing moderate to marked symptomatic relief.

At discharge, the patient was counselled regarding the chronic and relapsing nature of the disease and was advised to:

- Maintain regular follow-up (every 1 month)
- Avoid dietary and lifestyle factors aggravating Vata and Rakta
- Follow Dinacharya and Ritucharya tailored to her constitution

International Journal of Ayurveda360 | 2025; 1(6)

10.63247/3048-7390.vol.1.issue6.6

480

Singh R, Khagram R. Case Report: SLE Treated as Vatapradhana Vatarakta

| Site of Pain        | Before<br>Virechana | After<br>Virechana | After<br>Ksheera<br>Basti | After<br>Follow-up | Site of Pain          |
|---------------------|---------------------|--------------------|---------------------------|--------------------|-----------------------|
| Bilateral<br>Elbows | 9                   | 5                  | 3                         | 0                  | Bilateral<br>Elbows   |
| Bilateral<br>Hands  | 9                   | 6                  | 2                         | 0                  | Bilateral<br>Hands    |
| Bilateral Feet      | 10                  | 7                  | 4                         | 1                  | <b>Bilateral Feet</b> |
| Bilateral<br>Knees  | 10                  | 7                  | 3                         | 1                  | Bilateral<br>Knees    |

Table 9. Pain Assessment (VAS Score)

# Table 10. Assessment of Joint Stiffness (Grading System)

| Stiffness<br>Grade | Description                                             | Before<br>Virechana | After<br>Virechana | After<br>Ksheera<br>Basti | After<br>Follow-<br>up |
|--------------------|---------------------------------------------------------|---------------------|--------------------|---------------------------|------------------------|
| 0                  | No stiffness                                            | 0                   | -                  | _                         | —                      |
| 1                  | Mild (able to perform daily routine without difficulty) | 0                   | _                  | 1                         | 1                      |
| 2                  | Moderate (difficulty performing daily activities)       | 0                   | 2                  | _                         | _                      |

# Table 11. Assessment of Swelling (Measured in Inches)

| Joint Area                                  | Side | Before Virechana | After Virechana | After Ksheera<br>Basti |  |
|---------------------------------------------|------|------------------|-----------------|------------------------|--|
| Elbow Joints                                | R    | 8.5              | 8.1             | 8.0                    |  |
|                                             | L    | 8.5              | 8.2             | 8.0                    |  |
| Hands                                       | R    | 8.3              | 8.0             | 7.5                    |  |
|                                             | L    | 8.3              | 7.9             | 7.4                    |  |
| Feet                                        | R    | 11.3             | 10.1            | 9.5                    |  |
|                                             | L    | 11.5             | 10.4            | 9.4                    |  |
| Knee Joints                                 | R    | 16.9             | 16.1            | 15.0                   |  |
|                                             | L    | 16.5             | 15.6            | 14.9                   |  |
| Discussion Vunchang and Sthambhang align vi |      |                  |                 |                        |  |

# Discussion

The clinical manifestation of Systemic Lupus Erythematosus (SLE) in this case including pain, stiffness, joint swelling, intermittent fever, and blackish discoloration—can be appropriately correlated with Vatapradhana Vatarakta in Ayurvedic classics. Symptoms such as Dhamani Anguli Sandhinam Sankocha, Atiruk, Karshnya, Shyava Varna Shotha, *Kunchana*, and *Sthambhana* align with the observations in this case[5].

Given the Vata-Rakta Dushti and chronicity of symptoms, along with a background of long-term steroid use, a *Mridu Shodhana* [6] approach was warranted. Virechana Karma using Aragvadhadi Avaleha[7] was selected as it is Snigdha and suitable for Sukumara

International Journal of Ayurveda360 | 2025; 1(6)

*Purusha* and *Vata*-predominant disorders.

Charaka has described Ksheera Basti (milk-based enema) as the prime line of treatment in Vatarakta. The chosen decoctions-Dashamoola and Punarnavashtaka \_ possess antiinflammatory (Shothahara) and analgesic (Shulahara) properties. They are also effective in Raktaprasadana and Twakdoshahara.

- *Guduchi*, known as the *Agryadravya* in *Vatarakta*[8], was used both in *Ghrita*[9] and *Kalka* forms. It has *Tikta Rasa, Rasayana* action[10], and helps pacify *Tridoshas*.
- *Madhu* and *Saindhava*, due to their *Yogavahi* nature, enhance absorption and bioavailability of the *Basti Dravyas*.
- The combined effect of *Basti Karma* significantly reduced symptoms by clearing vitiated *Vata* and nourishing affected tissues.

This integrative approach proved effective in managing autoimmune inflammation by providing subjective relief, improving joint function, and enhancing quality of life.

# **Patient Perspective**

The patient expressed satisfaction and gratitude with the outcome of the treatment. She was particularly relieved

International Journal of Ayurveda360 | 2025; 1(6)

by the rapid reduction in symptoms and regained her ability to perform daily tasks. She acknowledged the seriousness of the illness only after understanding its autoimmune nature post-discharge and appreciated the effectiveness of Ayurveda in managing her chronic condition.

#### Image No. 2 : Before Treatment



Image No. 3: After Treatment



# Conclusion

SLE, an autoimmune multisystemic disorder, can be effectively correlated with *Vatapradhana Vatarakta* in *Ayurveda*. The integrative *Ayurvedic* protocol involving *Mridu Virechana* with

#### Singh R, Khagram R. Case Report: SLE Treated as Vatapradhana Vatarakta

Araqvadhadi Avaleha followed by Ksheera Basti prepared with Dashamoola. Punarnavashtaka, and Guduchi formulations resulted in significant symptomatic relief.

Though there was no remarkable change in laboratory parameters, subjective clinical improvement was

# **References:**

[1] Malaviya, A. N., Singh, R. R., Singh, Y.
N., Kapoor, S. K., & Kumar, A. (1993).
Prevalence of Systemic Lupus
Erythematosus in India. Lupus, 2(2),115-118.

[2] Carakasamhita, Cikitsasthana,
 Vatashonitachikistam, 29/2. Available
 from <u>http://niimh.nic.in/ebooks/ecaraka/</u>
 (Accessed on 15/04/2025)

**[3]** Carakasamhita, Cikitsasthana, Vatashonitachikistam, 29/10-11. Available from <u>http://niimh.nic.in/ebooks/ecaraka/</u> (Accessed on 15/04/2025)

[4] Carakasamhita, Cikitsasthana, Vatashonitachikistam, 29/7. Available from <u>http://niimh.nic.in/ebooks/ecaraka/</u> (Accessed on 15/04/2025)

**[5]** Carakasamhita, Cikitsasthana, Vatashonitachikistam, 29/24. Available from <u>http://niimh.nic.in/ebooks/ecaraka/</u> (Accessed on 15/04/2025) substantial, underlining the efficacy of *Ayurvedic* interventions in chronic autoimmune conditions.

# **Informed Consent**

Written informed consent was obtained from the patient for publication of this case report and accompanying data.

[6] Carakasamhita, Cikitsasthana, Vatashonitachikistam, 29/41. Available from <u>http://niimh.nic.in/ebooks/ecaraka/</u> (Accessed on 15/04/2025)

[7] Carakasamhita, Kalpasthana, Chaturangulakalpa, 08/12. Available from <u>http://niimh.nic.in/ebooks/ecaraka/</u> (Accessed on 15/04/2025)

[8] Carakasamhita,Sutrasthana, Vatashonitachikistam, 29/88. Available from <u>http://niimh.nic.in/ebooks/ecaraka/</u> (Accessed on 15/04/2025)

**[9]** Chakradatta of Sri Chakrapanidatta with Vaidayprabha Hindi commentry by Dr.Indradeva Tripathi, Chaukhambha Sanskrit Sansthan Varanasi ,Third Edition 1997 Amavatacikitsa verse -58,page 170.

**[10]** Carakasamhita, Sutrasthana, Deerghanjiviteeya, 1-3/30. Available from <u>http://niimh.nic.in/ebooks/ecaraka/</u> (Accessed on 15/04/2025).